PLRX vs INVA vs GILD vs PRGO vs MCK

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (6. 4x forward), making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus McKesson Corporation at 20. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +313.

0%, compared to -96. 6% for Pliant Therapeutics, Inc. (PLRX). Over 10 years, the gap is even starker: MCK returned +337. 8% versus PLRX's -94. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

10β versus Pliant Therapeutics, Inc. 's 1. 14β — meaning PLRX is approximately -1211% more volatile than MCK relative to the S&P 500. On balance sheet safety, Pliant Therapeutics, Inc. (PLRX) carries a lower debt/equity ratio of 16% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus 0. 0% for PLRX. At the gross margin level — before operating expenses — GILD leads at 78. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

2x forward P/E versus 17. 7x for McKesson Corporation — 12. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 229. 4% to $36. 20.

In this comparison, PRGO (10.

5% yield), GILD (2. 5% yield), MCK (0. 4% yield) pay a dividend. PLRX, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

10), +337. 8% 10Y return). Both have compounded well over 10 years (MCK: +337. 8%, PLRX: -94. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLRX is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; GILD is a mid-cap quality compounder stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap quality compounder stock. GILD, PRGO pay a dividend while PLRX, INVA, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.